Evidence map›Paper›PMID 42211755›Full record

ArticleHuman mutation2026

Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.

Chaozhi Tang, Yifan Liu, Tian-Long Wang, Jiakang Ma, Weihua Chen, Xiang Liu, Jingdong Xue, Lin Ye, Feng Yue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chaozhi TangDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0009-0001-6964-2058
Yifan LiuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0000-0001-7885-6990
Tian-Long WangDepartment of Urology, Shanghai Eighth People's Hospital, Shanghai, China.
Jiakang MaThe First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Shanghai, China, haust.edu.cn.
Weihua ChenDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.
Xiang LiuDepartment of Urology, Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0000-0003-4426-1985
Jingdong XueDepartment of Urology, Shanghai Eighth People's Hospital, Shanghai, China.ORCID https://orcid.org/0000-0001-8297-0948
Lin YeDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.ORCID https://orcid.org/0000-0002-3304-4558
Feng YueDepartment of Urology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, Guangdong, China, gzhmc.edu.cn.ORCID https://orcid.org/0009-0006-9220-7616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the transcriptomic level, several molecular subtyping schemes have been established to elucidate the intrinsic heterogeneity of urothelial carcinoma and to inform prognostic assessment and therapeutic guidance. However, a unified molecular classification scheme characterizing genomic alterations is lacking. Unsupervised and supervised clustering identified two distinct mutational signature subtypes. Kaplan-Meier analysis demonstrated that patients with the MUT2 subtype had a higher risk of death than those with the MUT1 subtype across multiple cohorts, including IMvigor210 (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.27-2.37;

Indexed as

Single-Cell AnalysisUrinary Bladder NeoplasmsAgedCluster AnalysisFemaleHumansMaleMiddle AgedMutationPrognosisSmokersSurvival AnalysisTumor MicroenvironmentUnsupervised Machine Learningimmunotherapy responseprognostic assessmentsignature subtypesurothelial carcinoma

Identifiers

PMID42211755
PMCPMC13213714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.